Journal of clinical haematology最新文献

{"title":"Lower 24-Month Relative Survival among Black Patients with Non- Hodgkin's Lymphoma: An Analysis of the SEER Data 1997-2015.","authors":"Maria J Nieto,&nbsp;Zhen Li,&nbsp;Hasan Rehman,&nbsp;Muhammad Wasif Saif","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Recent progress in the therapies used in patients with Non- Hodgkin's lymphoma has improved survival. The incidence has been reported to be decreasing in the last few years, accounting for 4% of all cancers. This study analyzed time trends for incidence, mortality, and prevalence of NHL.</p><p><strong>Methods: </strong>We analyzed the SEER Cancer Database from 1997 to 2015. Join point regression analysis was used to determine age-adjusted incidence rates, 24-month relative survival rate, and to identify racial/ethnic groups with a lower survival.</p><p><strong>Results: </strong>The trend in incidence of NHL decreased between 2008 and 2011 at an annual percentage change rate of 3.74%. The male predominance among NHL patients between 1997-2015 was 57%. The number of male patients affected with NHL has been similar in the last 20 years. Female predominance with NHL was higher in 1998 at 46 %, and lower in 2010 at 42.85%. The 24-month relative survival rate was higher among white patients as compared to black patients with NHL.</p><p><strong>Conclusions: </strong>Our analysis demonstrated that the incidence of Non-Hodgkin's Lymphoma has decreased among minorities; however, the outcomes are inferior in terms of survival. This analysis showed an inferior 24-month relative survival rate among black patients compared with white patients. This analysis demonstrates the need for further research in NHL to determine the biological differences and social factors that influence the lower survival among black patients with NHL.</p>","PeriodicalId":87297,"journal":{"name":"Journal of clinical haematology","volume":"2 1","pages":"5-13"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8026162/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25573362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Flavopiridol (Alvocidib), a Cyclin-dependent Kinases (CDKs) Inhibitor, Found Synergy Effects with Niclosamide in Cutaneous T-cell Lymphoma.","authors":"Xu Hannah Zhang,&nbsp;Jack Hsiang,&nbsp;Steven T Rosen","doi":"10.33696/haematology.2.028","DOIUrl":"https://doi.org/10.33696/haematology.2.028","url":null,"abstract":"<p><p>Flavopiridol (FVP; Alvocidib), a CDKs inhibitor, is currently undergoing clinical trials for treatment of leukemia and other blood cancers. Our studies demonstrated that FVP also inhibited p38 kinases activities with IC₅₀ (μM) for p38α: 1.34; p38 β: 1.82; p38γ: 0.65, and p38δ: 0.45. FVP showed potent cytotoxicity in cutaneous T-cell lymphoma (CTCL) Hut78 cells, with IC₅₀ <100 nM. NMR analysis revealed that FVP bound to p38γ in the ATP binding pocket, causing allosteric perturbation from sites surrounding the ATP binding pocket. Kinomic profiling with the PamGene platform in both cell-based and cell-free analysis further revealed dosage of FVP significantly affects downstream pathways in treated CTCL cells, which suggested a need for development of synergistic drugs with FVP to prevent its clinically adverse effects. It led us discover niclosamide as a synergistic drug of FVP for our future <i>in vivo</i> study.</p>","PeriodicalId":87297,"journal":{"name":"Journal of clinical haematology","volume":"2 2","pages":"48-61"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248901/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39158047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chemotherapy Promotes Release of Exosomes Which Upregulate Cholesterol Synthesis and Chemoresistance in AML Blasts.","authors":"Chang-Sook Hong,&nbsp;Michael Boyiadzis,&nbsp;Theresa L Whiteside","doi":"10.33696/haematology.2.026","DOIUrl":"https://doi.org/10.33696/haematology.2.026","url":null,"abstract":"Extracellular vesicles (EVs) are emerging as a key mediator of intercellular communication as well as a major mechanism of functional reprogramming of cells in disease [1-2]. All cells produce EVs, which freely circulate and are found in all body fluids. EVs are heterogenous, consisting of subsets of vesicles with different sizes, distinct origins, and various functions (Figure 1). They mediate a broad variety of biological events ranging from cellular activation, inflammation, blood coagulation, angiogenesis, cellular transport, and others. Among these vesicles, a subset of small EVs (30-150 nm in diameter) originating from multivesicular bodies (MVBs) in parent cells and referred to as small extracellular vesicles (sEVs) carry proteomic, genomic and functional signatures that resemble those of parent cells and are, therefore, taken as surrogates of parent cells. In cancer, tumor-derived exosomes (TEX) reflect characteristics of tumor cells and are considered candidates for “liquid tumor biopsy” [3]. Emerging evidence shows that TEX are a major sEV subset in plasma of patients with cancer, including hematologic malignancies [4].","PeriodicalId":87297,"journal":{"name":"Journal of clinical haematology","volume":"2 2","pages":"36-39"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8294665/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39211251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nanoscale Chitosan-Based Hemostasis Membrane","authors":"S. Biranje, P. Madiwale, R. Adivarekar","doi":"10.33696/HAEMATOLOGY.1.013","DOIUrl":"https://doi.org/10.33696/HAEMATOLOGY.1.013","url":null,"abstract":"Excessive bleeding or hemorrhage in traumatic injuries is the leading preventable cause of death in the combat and civilian trauma centers. Nearly 50% of military deaths, 90% of military battlefield casualties, and 33-56% mortalities in civilian’s surgical bleeding are associated with severe bleeding and can be prevented [1]. Hence, significant and rapid hemostasis or bleeding control require innovative strategies with easy to use, stable, and inexpensive processing. Furthermore, the developed hemostatic material should ensure biocompatibility and biodegradability with non-immunogenic properties. To date, a wide variety of hemostatic powders, dressings, and bandages have been investigated as useful materials in reducing hemorrhage. Unfortunately, studies have shown several limitations, especially in managing penetrating injuries, where it is hard to stop bleeding through hemostatic bandages and dressings alone [2]. Also, the most widely used hemostatic powders are still challenging to apply in the wounded area during excessive bleeding [3].","PeriodicalId":87297,"journal":{"name":"Journal of clinical haematology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45865795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anticancer Activity of S-Glycosylated Quinazoline Derivatives","authors":"A. Khodair, M. A. Alsafi","doi":"10.33696/HAEMATOLOGY.1.011","DOIUrl":"https://doi.org/10.33696/HAEMATOLOGY.1.011","url":null,"abstract":"72 Breast cancer is the most frequent malignancy in females. Due to its major impact on the population, this disease represents a critical public health problem that requires further research at the molecular level to define its prognosis and specific treatment. Basic research is required to accomplish this task and this involves cell lines as they can be widely used in many aspects of laboratory research and, particularly, as in vitro models in cancer research. MCF-7 is a commonly used breast cancer cell line, that has been promoted for more than 40 years by multiple research groups but its characteristics have never been gathered in a consistent review article. The current paper provides a broad description of the MCF7 cell line, including the molecular profile, proliferation, migration, invasion, spheroid formation, its involvement in angiogenesis and lymphangiogenesis, and its interaction with the mesenchymal stem cells [1].","PeriodicalId":87297,"journal":{"name":"Journal of clinical haematology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43569293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gemcitabine in the Era of Cancer Immunotherapy","authors":"Katarzyna Piadel, A. Dalgleish, P. Smith","doi":"10.33696/HAEMATOLOGY.1.016","DOIUrl":"https://doi.org/10.33696/HAEMATOLOGY.1.016","url":null,"abstract":"Gemcitabine is a synthetic pyrimidine nucleoside analogue which is administered intravenously as a chemotherapeutic to treat numerous cancers. Gemcitabine requires transport into cells and activation by phosphorylation, the resulting gemcitabine triphosphate is incorporated into newly synthesized DNA during cell division, inhibiting further DNA synthesis and causing cell death. Gemcitabine is used to treat cancers including those of the pancreas, lung, breast, colon, and ovary either as first or second line treatments as a single agent or in combination.","PeriodicalId":87297,"journal":{"name":"Journal of clinical haematology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43194063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unmasking the Master of Disguise: Defining Advancements in Diagnosis of Intravascular Large B-cell Lymphoma","authors":"M. Brunner, Luke D. Zurbriggen, Julie E. Chang","doi":"10.33696/HAEMATOLOGY.1.019","DOIUrl":"https://doi.org/10.33696/HAEMATOLOGY.1.019","url":null,"abstract":"Intravascular B cell lymphoma (IVBCL) is notoriously difficult to diagnose as the clinical manifestations are protean, and the patterns seen with routine labs and imaging are non-specific [1]. Furthermore, the disease follows an aggressive course and is often fatal within a matter of weeks to months from symptom onset, unless recognized and treated appropriately [2]. This has historically meant that diagnosis was made at autopsy for many patients. Over the past few decades, however, scientific and clinical literature have slowly accumulated to better characterize and raise clinical awareness of this disease. In this paper, we will review the characteristics that make this diagnosis challenging, and then discuss new and emerging diagnostic avenues.","PeriodicalId":87297,"journal":{"name":"Journal of clinical haematology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44880136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeted Immune Therapy as Example of Paul Ehrlich’s “Magic Bullets” Developed More than 100 Years Ago","authors":"G. Zugmaier","doi":"10.33696/HAEMATOLOGY.1.017","DOIUrl":"https://doi.org/10.33696/HAEMATOLOGY.1.017","url":null,"abstract":"121 In the article by Gerhard Zugmaier, Antibodies in hematology by the example of acute lymphoblastic leukemia, Der Internist 10 (2019) 1032–1035 [1], the application of antibodies in hematology was described by using the example of acute lymphoblastic leukemia. Antibodies have become an essential element of treatment for patients with hematological tumors. This concept was developed more than 100 years ago in a different context [2]. The German physician Paul Ehrlich (1854-1915) said, that for the defense against bacteria “antibodies” were be responsible [2,4]. In the antibodies Ehrlich saw therapeutic compounds, that like “magic bullets” would find their target and only destroy this target without affecting the organism. Paul Ehrlich became inspired by a scene in the German opera “Der Freischütz” (“The marksman”) by the composer Carl Maria von Weber [3]. In this opera a certain kind of bullets, “free bullets”, which were magic bullets, played a major role, because they always found their target. In 1878 Paul Ehrlich became resident and later attending physician at the Charité in Berlin. There, he worked closely together with Robert Koch, Emil von Behring, and Shibasaburo Kitasato. The chairman of the department, the famous internist Theodor von Frerichs, gave Paul Ehrlich enough space to conduct his experiments. Starting from 1882 Ehrlich investigated the acid resistance of the tuberculosis mycobacterium just discovered by Robert Koch and developed a method of dyeing the mycobacterium, thereby being able to detect it in the organism. Koch and Frerichs were important supporters of Ehrlich [4]. In 1890, Ehrlich was appointed by Koch to a position at the newly founded Institute for infectious Disease, the Robert Koch Institute. Ehrlich’s groundbreaking research in immunology started at that time. Later, in 1899, Ehrlich was appointed as Chairman of the newly found Institute for Experimental Therapy in Frankfurt, the Georg Speyer Haus, in which until this day important research has been conducted. There he continued his groundbreaking research in Immunology and Cancer Research. In 1908, Paul Ehrlich received the Nobel prize for Medicine [4]. Ehrlich’s great ability for abstract concepts enabled the creation of terms such as ‘receptor’ [2]. In this context he also developed the concept of “magic bullets”, which are drugs that move straight to their target. Targeted compounds attack pathogens that express the target and leave tissue alone that does not express the target [2]. It turned out later that the concept of magic bullets was not confined to bacterial infections and could be extrapolated from infectious disease to malignant tumors. Surface antigens on tumor cells could serve as target of these magic bullets.","PeriodicalId":87297,"journal":{"name":"Journal of clinical haematology","volume":"110 30","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41251378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anticancer and Antiviral Activity of the Pyridine-Biphenyl Glycoside System","authors":"A. Khodair, A. Attia, E. Gendy, Y. Elshaier, M. El-Magd","doi":"10.33696/HAEMATOLOGY.1.020","DOIUrl":"https://doi.org/10.33696/HAEMATOLOGY.1.020","url":null,"abstract":"Ahmed I. Khodair1*, Adel M. Attia1, Eman A. Gendy1, Yaseen A. M. M. Elshaier2, Mohammed A. El-Magd3 1Chemistry Department, Faculty of Science, kafrelshiekh University, El-Geish Street, kafrelshiekh, Post Box 33516, Egypt 2Department of Organic and Medicinal chemistry, Faculty of Pharmacy, University of Sadat City, Menoufiya, 32897, Egypt 3Anatomy Department, Faculty of Veterinary Medicine, Kafrelshiekh University, El-Geish Street, kafrelshiekh, Post Box 33516, Egypt","PeriodicalId":87297,"journal":{"name":"Journal of clinical haematology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47943039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of Diagnostic and Treatment Centers in the Second Wave of COVID-19","authors":"Mahdieh Motie, R. Dehnavieh, Khalil Kalavani","doi":"10.33696/haematology.1.007","DOIUrl":"https://doi.org/10.33696/haematology.1.007","url":null,"abstract":"54 COVID-19 has challenged global health and affected many countries. The disease had infected more than 16 million people and killed over 650,000 ones by the end of July 2020. According to Sahu et al., COVID-19 epidemic is the third most common coronavirus in the 21st century, resulting in numerous deaths all over the world [1]. It has caused severe psychological stress and increased hospital visits along with increased tiredness and burnout of medical staff. The disease has also raised many problems for the management of hospitals and diagnostic-treatment centers, so that many of them have no capacity to receive patients [2].","PeriodicalId":87297,"journal":{"name":"Journal of clinical haematology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47266707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}